Last reviewed 2026-06-02 · How we verify

Tasmadem (MOTRETINIDE)

Phase 2 active Small molecule

Tasmadem (generic name: MOTRETINIDE) is a motretinide drug. It is currently in Phase 2 development for Acne vulgaris.

Tasmadem works by inhibiting the production of sebum, a key factor in the development of acne.

Tasmadem, also known as Motretinide, is a small molecule drug in the motretinide class. It is used to treat Acne vulgaris. The commercial status of Tasmadem is currently unknown, and it is not clear if it is patented or available as a generic. As a pharma professional, it is essential to consider the potential safety risks associated with Tasmadem, although specific details are not available. Further research is necessary to understand its pharmacokinetic properties and clinical use.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MOTRETINIDE
Drug class	motretinide
Modality	Small molecule
Therapeutic area	Dermatology
Phase	Phase 2

Mechanism of action

Think of sebum like the oil in your car. When your skin produces too much sebum, it can clog pores and lead to acne. Tasmadem helps reduce sebum production, making it harder for acne to form.

Approved indications

Acne vulgaris

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tasmadem CI brief — competitive landscape report
Tasmadem updates RSS · CI watch RSS

Frequently asked questions about Tasmadem

What is Tasmadem?

Tasmadem (MOTRETINIDE) is a motretinide drug, indicated for Acne vulgaris.

How does Tasmadem work?

Tasmadem works by inhibiting the production of sebum, a key factor in the development of acne.

What is Tasmadem used for?

Tasmadem is indicated for Acne vulgaris.

What is the generic name of Tasmadem?

MOTRETINIDE is the generic (nonproprietary) name of Tasmadem.

What drug class is Tasmadem in?

Tasmadem belongs to the motretinide class. See all motretinide drugs at /class/motretinide.

What development phase is Tasmadem in?

Tasmadem is in Phase 2.

Drug class: All motretinide drugs
Therapeutic area: All drugs in Dermatology
Indication: Drugs for Acne vulgaris

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing